Moreover, we excluded genetic predisposition syndromes, knowing that therapeutic management is different in these patients who may have multiple NETs in the same organ, such as pancreatic NETs in MEN1 patients. This evidence concerns the gene MEN1 and pancreatic neuroendocrine tumor.